Yuexin Cheng

Yuexin Cheng

Auto-generated profile, based on publicly available information

Yuexin Cheng

Department of Hematology, The First People’s Hospital of Yancheng, The Yancheng Clinical College of Xuzhou Medical University, Yancheng, People’s Republic of China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2024 in Cancer Medicine
Verified
Journal Article
Open access
LWLingling Wang
Lingling Wang
LYLei Yang
Lei Yang
FGFangshu Guan
Fangshu Guan
JCJing Chen
Jing Chen
YCYuexin Cheng
Yuexin Cheng
YZYi Zhao
Yi Zhao
There are limited studies on mutation profiling for Peripheral T‐cell lymphomas (PTCL) in the Chinese population. We retrospectively analyzed the clinical and genetic landscape of 66 newly diagnosed Chinese patients. Targeted next‐generation sequencing (NGS) was performed for tissues from these patients. At least one mutation was detected in 60 (90.9%) patients, with a median number of 3 (0–7) mutations, and 32 (48.5%) cases detected with more than 4 mutations. The genes with higher mutation frequencies were TET2, RHOA, DNMT3A, IDH2, TP53, STAT3, and KMT2D respectively. When mutant genes are classified by functional group, the most prevalent mutations are related to epigenetics and signal transduction. IPI ≥2, PIT ≥2, and failure to achieve partial remission (PR) were factors for inferior progression‐free survival (PFS) and overall survival (OS). Multivariate analysis showed TP53 was an adverse factor for PFS (HR, 3.523; 95% CI, 1.262–9.835; p = 0.016), and KMT2D was an adverse factor for OS (HR, 10.097; 95% CI, 1.000–101.953; p = 0.048). Mutation profiling could help differentiate distinct types of PTCL and serve as a useful tool for determining treatment options and prognoses.

18 July 2024 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
LWLingling Wang
Lingling Wang
CXConglin Xi
Conglin Xi
XZXinyu Zheng
Xinyu Zheng
YHYongfen Huang
Yongfen Huang
HXHao Xu
Hao Xu
YCYuexin Cheng
Yuexin Cheng
Background: Familial 46, XY Disorder of Sexual Development (DSD) was discovered in a Ph+, BCR::ABL1P210+ Acute Lymphoblastic Leukemia (ALL) female with RCBTB2::LPAR6 fusion gene. Siblings developing 46, XY DSD are extremely rare. Patients with 46, XY DSD have much higher rates of gonadal cancers. Nevertheless, the incidence of hematologic malignancies in patients with DSDs has received little attention. RCBTB2::LPAR6 is a rarely reported fusion gene in ALL.Case presentation: Herein, we report a rare case of a newly diagnosed Ph+, BCR::ABL1P210+ ALL patient who was 77 years old and female by social sex. Whole Exome Sequencing (WES) and RNA sequencing revealed TET2 and NF1 mutations in addition to a rarely reported RCBTB2::LPAR6 fusion gene and 17 other genes with uncertain clinical significance. The patient was surprisingly found to have a male karyotype. On ultrasound, neither the uterus nor the ovaries were discernible. A detailed family and marital history revealed that the patient had undergone surgery at an early age for an unexplained inguinal mass. She had slow pubertal development, scanty menstruation, and few overtly feminine characteristics. She had three marriages, but none succeeded in getting pregnant. The patient had never sought therapy for infertility due to the inaccessibility of medical treatment and a lack of medical knowledge. Her sister, 73 years old and female by social sex, who had amenorrhea in adolescence and was unable to conceive, had the same experience. To our surprise, she also had a male karyotype.Conclusions: Due to the absence of long-term social attention and follow-up, studies on the incidence of hematologic malignancies in patients with 46, XY DSD are incredibly uncommon. Siblings developing 46, XY DSD is extremely rare. We report the oldest patient diagnosed with 46, XY DSD. There have not yet been any reports of familial 46, XY DSD with a concurrent diagnosis of Ph+BCR::ABL1P210+ALL with a rarely reported RCBTB2::LPAR6 fusion gene.

27 November 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
LWLingling Wang
Lingling Wang
CXConglin Xi
Conglin Xi
YHYongfen Huang
Yongfen Huang
HXHao Xu
Hao Xu
YMYuqing Miao
Yuqing Miao
YCYuexin Cheng
Yuexin Cheng
Waldenstrom’s macroglobulinemia (WM) is a rare and indolent B-cell lymphoma. To investigate the type and survival of hematologic secondary malignancies (SMs) in Chinese patients with WM, we retrospectively reviewed the characteristics of 102 patients with WM from February 2002 to May 2023 in our center. Four men and two women were diagnosed with hematologic SMs. Of the six patients with hematologic SMs, one was diagnosed with acute myeloid leukemia (AML), one with multiple myeloma (MM), one with myelodysplastic syndrome (MDS), one with B-cell acute lymphoblastic leukemia (B-ALL), and two with diffuse large B-cell lymphoma (DLBCL). The median age was 65.5 years (56–74 years). The median interval time between diagnosis of WM and hematologic SMs was 39.5 months (10–117 months). Among those with WM with hematologic SMs, five died and one survived. Overall survival (OS) was just 33 months (12–119 months) on median. A total of 32 patients died and 64 survived in the group of WM without hematologic SMs, and the median OS was 82 months (3–250 months). This is the first study in the Chinese population on hematologic SMs in WM. The purpose of this study was to investigate the prognosis of hematologic SMs in WM in the Chinese population, as well as to compare the population’s characteristics to those of other centers. We investigated the underlying causes further and presented a research strategy for our forthcoming investigation. We intend to investigate risk factors for SMs as well as more accessible screening methods.

18 September 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
LWLingling Wang
Lingling Wang
YMYuqing Miao
Yuqing Miao
YCYuexin Cheng
Yuexin Cheng
Venetoclax is effective in treating relapsed acute promyelocytic leukemia (APL), newly diagnosed pediatric APL, variant APL, and APL with central nervous system involvement. In newly diagnosed adult APL, venetoclax is rarely used. Herein, we present a case of newly diagnosed adult APL in a 35-year-old female with schizophrenia who received venetoclax as a cytoreduction therapy option. The patient was admitted with myocardial ischemia, the cardiac ultrasound indicating left ventricular ejection fractions (EF) of 44%, a 17-year history of schizophrenia, treated with ziprasidone, lorazepam, and clozapine. She developed differentiation syndrome (DS) shortly after receiving All-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) and experienced heart arrest. In the occurrence of DS, this young female encountered numerous therapeutic conundrums, including cytoreduction of hydroxyurea being ineffective, the potential psychological worsening caused by dexamethasone use, and the cardiotoxicity of anthracyclines. We administered venetoclax 20 mg once daily as a cytoreduction therapy. The white blood cells (WBC) dropped from 72.16×109/L to 5.19×109/L in 4 days, and the proportion of promyelocytes in the peripheral blood smear decreased from 78% to 10%. Tumor lysis syndrome (TLS) did not develop since the patient received good supportive treatment. For newly diagnosed adult patients with APL who are unresponsive to traditional cytoreduction therapy, venetoclax can be an effective option.

6 October 2026 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
PDF file
ZLZhen Li
Zhen Li
YHYanping Hao
Yanping Hao
JCJin Chen
Jin Chen
XLXuan Liu
Xuan Liu
WXWeilin Xu
Weilin Xu
YCYuexin Cheng
Yuexin Cheng
Background/Aims: Monitoring endoscopic inflammation in Crohn’s disease (CD) is difficult. This study examined whether X-C motif chemokine ligand 1 (XCL1) is associated with endoscopic activity, as defined by the Simple Endoscopic Score for Crohn’s Disease (SES-CD). Materials and Methods: This was a single-center observational biomarker study. Peripheral blood mononuclear cell (PBMC) transcriptome sequencing was performed in 6 patients with newly diagnosed CD and 6 controls without inflammatory bowel disease. XCL1 protein expression was evaluated using immunohistochemistry and western blotting in 12 intestinal biopsy samples. Serum XCL1 levels were measured using enzyme-linked immunosorbent assay in 125 patients with CD and 40 controls. Patients with CD were classified according to the SES-CD. Correlation, logistic regression, receiver operating characteristic, bootstrap validation, and treatmentadjusted analyses were performed. Results: XCL1 was upregulated in PBMCs and increased in the intestinal mucosa of patients with active disease. Serum XCL1 levels differed among controls and SES-CD groups (P < .001). In patients with CD, serum XCL1 correlated with SES-CD (r = 0.692), fecal calprotectin (FC) (r = 0.573), Crohn’s Disease Activity Index (r = 0.420), and C-reactive protein (CRP) (r = 0.433; all P < .001). XCL1 remained associated with endoscopic activity after adjustment (odds ratio = 1.005, 95% CI= 1.001-1.008, P = .012). The areas under the curve were 0.76 for XCL1, 0.81 for FC, and 0.85 for the XCL1+FC+CRP model. Conclusion: Although serum XCL1 was associated with SES-CD–defined endoscopic activity, its performance was lower than that of FC. XCL1 may serve as an exploratory adjunctive serum marker but requires further validation. Cite this article as: Li Z, Hao Y, Chen J, Liu X, Xu W, Cheng Y. Serum X-C motif chemokine ligand 1 is associated with endoscopic activity in Crohn’s disease: A clinical biomarker study. Turk J Gastroenterol. Published online October 06, 2026. doi: 10.5152/tjg.2026.26373.

28 August 2026 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
LWLingling Wang
Lingling Wang
YHYongfen Huang
Yongfen Huang
HCHui Chen
Hui Chen
JDJianming Dong
Jianming Dong
HXHao Xu
Hao Xu
YCYuexin Cheng
Yuexin Cheng
Waldenstrom’s macroglobulinemia (WM) is characterized by familial aggregation. The study displayed the characteristics and outcomes of patients with WM in siblings. Ten cases (five pairs) were recognized as WM in siblings. The earliest pair (cases 3 and 4) was identified in 2002 and 2005, respectively, while the recent pair (cases 7 and 8) was confirmed in 2022. Males accounted for 90%. The median age at diagnosis was 65.5 years (range, 51–71 years). Rituximab-based immunochemotherapy was initiated in three patients, whereas regimens based on nucleoside analogs and alkylating drugs were initiated in five patients. As of December 2024, three patients died from severe infection, while one died from traumatic injury. Our investigation discovered no significant difference between WM in siblings and sporadic WM in terms of gender, age, ECOG score, B symptoms, with or without BTKi exposure, IPSS-WM score, Hb, PLT, LDH, β2-MG, IgM, albumin, hepatosplenomegaly, lymphadenopathy, and MYD88L265P. Median overall survival was 230 months for patients with familial WM among siblings and 96 months for those with sporadic WM (p = 0.2, HR: 0.6, 95% CIs: 0.2-1). This study provided an overview of the screening initiatives for WM in siblings in the hospital population and follow-up results for five pairs of WM in siblings. The incidence of WM in siblings in the real world may be underestimated.